Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.

Abstract excerpt

Ibrutinib, as the first Bruton's tyrosine kinase (Btk) inhibitor, has been shown to have clinically significant activity in leukemias and lymphomas. However, the initially responsive tumors will develop resistance during the process of treatment in few patients. Here, we summarized the mechanism of acquired resistance and suggested the next-generation Btk inhibitors that override the target resistance. Moreover,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenine
• Share to Agammaglobulinaemia Tyrosine Kinase
• Share to Molecular Structure